Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5660MR)

This product GTTS-WQ5660MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5660MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8318MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ10832MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ7306MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ14995MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ9238MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ11666MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ12850MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ9390MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW